In search of distinct MS-related fatigue subtypes: results from a multi-cohort analysis in 1.403 MS patients

被引:11
|
作者
Pust, Gesa E. A. [1 ,2 ]
Poettgen, Jana [1 ]
Randerath, Jennifer [2 ,3 ]
Lau, Stephanie [1 ]
Heesen, Christoph [1 ,4 ]
Gold, Stefan M. [1 ,5 ,6 ]
Penner, Iris-Katharina [7 ,8 ]
机构
[1] Univ Klinikum Hamburg Eppendorf, Inst Neuroimmunol & Multiple Sklerose INIMS, ZMNH, Hamburg, Germany
[2] Univ Konstanz, Dept Psychol, Constance, Germany
[3] Univ Konstanz, Schmieder Fdn Sci & Res, Lurija Inst Rehabil & Hlth Sci, Allensbach, Germany
[4] Univ Klinikum Hamburg Eppendorf UKE, Klin & Poliklin Neurol, Hamburg, Germany
[5] Charite Univ Med Berlin, Klin Psychiat & Psychotherapie, Campus Benjamin Franklin, Berlin, Germany
[6] Charite Univ Med Berlin, Med Klin MS Psychosomat, Campus Benjamin Franklin, Berlin, Germany
[7] Heinrich Heine Univ Dusseldorf, Med Fac, Dept Neurol, Dusseldorf, Germany
[8] COGITO Ctr Appl Neurocognit & Neuropsychol Res, Dusseldorf, Germany
关键词
Fatigue; Assessment; Validation; Multiple sclerosis;
D O I
10.1007/s00415-019-09311-2
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Fatigue is among the most disabling symptoms in patients with multiple sclerosis (PwMS). The common distinction between cognitive and motor fatigue is typically incorporated in self-rating instruments, such as the Chalder Fatigue Questionnaire (CFQ), the Fatigue Scale for Motor and Cognitive Functions (FSMC) or the Modified Fatigue Impact Scale (MFIS). The present study investigated the factor structure of the CFQ, the FSMC and the MFIS utilizing exploratory (EFA) and confirmatory factor analysis (CFA) as well as exploratory structural equation modeling (ESEM). Data of 1.403 PwMS were analyzed, utilizing four samples. The first sample (N=605) was assessed online and split into two stratified halves to perform EFA, CFA, and ESEM on the CFQ and FSMC. The second sample (N=293) was another online sample. It served to calculate CFA and ESEM on the CFQ and FSMC. The third sample was gathered in a clinical setting (N=196) and analyzed by applying CFA and ESEM to the FSMC. The fourth sample (N=309) was assessed in a clinical setting and allowed to run a CFA and ESEM on the MFIS. Proposed factor structures of all questionnaires were largely confirmed in EFA. However, none of the calculated CFAs and ESEMs could verify the proposed factor structures of the three measures, even with oblique rotation techniques. The findings might have implications for future research into the pathophysiological basis of MS-related fatigue and could affect the suitability of such measures as outcomes for treatment trials, presumably targeting specific sub-components of fatigue.
引用
收藏
页码:1663 / 1673
页数:11
相关论文
共 49 条
  • [21] The effect of prolonged-release fampridine on cognitive performance, fatigue, depression and quality of life of MS patients: results from the Ignite study
    Bakirtzis, C.
    Konstantinopoulou, E.
    Minti, F.
    Mandoras, N.
    Nikolaidis, I.
    Tatsi, T.
    Afrantou, T.
    Ioannidis, P.
    Grigoriadis, N.
    EUROPEAN JOURNAL OF NEUROLOGY, 2018, 25 : 291 - 291
  • [22] Association of improvement in fatigue with improvement in depression and sleepiness in natalizumab-treated multiple sclerosis (MS) patients: results from the TYNERGY study
    Penner, I-K
    Celius, E. G.
    Fuchs, S.
    Schreiber, K.
    Berkoe, S.
    Sun, J.
    Falk, E.
    Svenningsson, A.
    JOURNAL OF NEUROLOGY, 2013, 260 : S69 - S69
  • [23] MS-Related Causes of Death and Clinical Outcomes in Patients from the 21-Year Long-Term Follow-up Study of Interferon Beta-1b
    Reder, A. T.
    Goodin, D.
    Ebers, G.
    Cutter, G.
    Rametta, M.
    Kremenchutzky, M.
    Oger, J.
    Langdon, D.
    Beckmann, K.
    MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (05) : 680 - 681
  • [24] Results from a multi-laboratory ocean metaproteomic intercomparison: effects of LC-MS acquisition and data analysis procedures
    Saito, Mak A.
    Saunders, Jaclyn K.
    McIlvin, Matthew R.
    Bertrand, Erin M.
    Breier, John A.
    Brisbin, Margaret Mars
    Colston, Sophie M.
    Compton, Jaimee R.
    Griffin, Tim J.
    Hervey, W. Judson
    Hettich, Robert L.
    Jagtap, Pratik D.
    Janech, Michael
    Johnson, Rod
    Keil, Rick
    Kleikamp, Hugo
    Leary, Dagmar
    Martens, Lennart
    McCain, J. Scott P.
    Moore, Eli
    Mehta, Subina
    Moran, Dawn M.
    Neibauer, Jaqui
    Neely, Benjamin A.
    Jakuba, Michael V.
    Johnson, Jim
    Duffy, Megan
    Herndl, Gerhard J.
    Giannone, Richard
    Mueller, Ryan
    Nunn, Brook L.
    Pabst, Martin
    Peters, Samantha
    Rajczewski, Andrew
    Rowland, Elden
    Searle, Brian
    Van Den Bossche, Tim
    Vora, Gary J.
    Waldbauer, Jacob R.
    Zheng, Haiyan
    Zhao, Zihao
    BIOGEOSCIENCES, 2024, 21 (21) : 4889 - 4908
  • [25] Clinical and biological activity of ST101, a peptide antagonist of C/EBPβ, in recurrent Glioblastoma (rGBM) patients. Results from the rGBM cohort of a multi-cohort Phase 2 Study
    Iwamoto, Fabio
    Buerki, Robin
    Butowski, Nicholas
    Peters, Katherine B.
    Williams, Anja
    Falchook, Gerald
    Rotolo, Jim
    Michel, Rob
    Kaesshaefer, Stephen
    Scuoppo, Claudio
    Vainstein-Haras, Abi
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
  • [26] CLINICAL AND PHARMACODYNAMIC BIOMARKER RESULTS FROM PORTER, A MULTI-COHORT PHASE 1 PLATFORM TRIAL OF COMBINATION IMMUNOTHERAPY FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS
    Galsky, Matthew
    Autio, Karen
    Wentzel, Kristopher
    Graff, Julie
    Friedlander, Terence
    Densmore, Julie
    Cabanski, Christopher
    Shotts, Kristin
    Howes, Tim
    Yu, Jia
    Eisenbeisz, Elaine
    Spasic, Marko
    Maddock, Stephen
    DaSilva, Diane
    Kumar, Dinesh
    Moore, Jonni
    Schretzenmair, Richard
    Lata, Jennifer
    Xu, Arron
    Reuschel, Emma
    Wani, Snehal
    Morrow, Matthew
    Skolnik, Jeffrey
    Santulli-Marotto, Sandra
    Padron, Lacey
    Butterfield, Lisa
    LaVallee, Theresa
    Bucktrout, Samantha
    Yellin, Michael
    Keler, Tibor
    Salvador, Lisa
    O'Donnell-Tormey, Jill
    Lucey, Vanessa
    Fairchild, Justin
    Dugan, Ute
    Bhardwaj, Nina
    Subudhi, Sumit
    Fong, Lawrence
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A580 - A580
  • [27] Cognition, Fatigue, Depression and Health-Related Quality of Life in Patients with Early MS From Australia: Baseline Data From CogniMS, A Worldwide Longitudinal Study
    Macdonell, R.
    Wicklein, E. M.
    Fredrikson, S.
    Langdon, D.
    MULTIPLE SCLEROSIS, 2010, 16 (02): : 267 - 267
  • [28] Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort A
    Wu, J.
    Zhu, L.
    Zhou, C.
    Shi, M.
    Chen, J.
    Zhao, L.
    Han, Z.
    Wang, C.
    Jiang, J.
    Yan, J.
    Wei, X.
    Mao, Y.
    Yang, X.
    Qin, Z.
    Tang, X.
    Zhang, J.
    ANNALS OF ONCOLOGY, 2023, 34 : S1510 - S1511
  • [29] Anlotinib plus chemotherapy as first-line therapy for patients with gastrointestinal tumor with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial, ALTER-G-001-cohort C
    Wu, Junwei
    Zhou, Chenfei
    Yan, Jun
    Han, Zhengxiang
    Wang, Chun
    Qin, Zhiquan
    Jiang, Jinling
    Wang, Chunbing
    Tang, Xinyu
    Zhu, Lingjun
    Chen, Jun
    Mao, Yong
    Zhu, Liangjun
    Wei, Xiaowei
    Shangguan, Chengfang
    Zhang, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [30] Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort C
    Wu, Junwei
    Zhou, Chenfei
    Yan, Jun
    Han, Zhengxiang
    Wang, Chun
    Qin, Zhiquan
    Jiang, Jinling
    Wang, Chunbin
    Tang, Xinyu
    Zhu, Lingjun
    Chen, Jun
    Mao, Yong
    Wei, Xiaowei
    Shangguan, Chengfang
    Zhang, Jun
    CANCER RESEARCH, 2024, 84 (07)